BOVen: Zanubrutinib, Obinutuzumab, and Venetoclax Yields 75% OS at 2 Years in High-Risk MCL
In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center presented phase 2 results for 25 patients with TP53 mutations.